tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Knight Therapeutics announces relaunch of MYFEMBREE in Canada
The FlyKnight Therapeutics announces relaunch of MYFEMBREE in Canada
12d ago
Knight Therapeutics announces relaunch of ORGOVYX in Canada
PremiumThe Fly
Knight Therapeutics announces relaunch of ORGOVYX in Canada
12d ago
Knight Therapeutics announces normal course issuer bid
PremiumThe Fly
Knight Therapeutics announces normal course issuer bid
2M ago
Knight Therapeutics’ Earnings Call Highlights Growth and Expansion
PremiumCompany Announcements
Knight Therapeutics’ Earnings Call Highlights Growth and Expansion
2M ago
Knight Therapeutics: Strong Financial Performance and Strategic Positioning Justify Buy Rating
PremiumRatings
Knight Therapeutics: Strong Financial Performance and Strategic Positioning Justify Buy Rating
2M ago
Knight Therapeutics Reports Record Revenue Amid Net Loss
PremiumCompany AnnouncementsKnight Therapeutics Reports Record Revenue Amid Net Loss
2M ago
Knight Therapeutics Achieves Record Revenues Amid Strategic Expansions
Premium
Company Announcements
Knight Therapeutics Achieves Record Revenues Amid Strategic Expansions
2M ago
Knight Therapeutics reports Q2 EPS (C$0.13) vs. (C$0.02) last year
Premium
The Fly
Knight Therapeutics reports Q2 EPS (C$0.13) vs. (C$0.02) last year
2M ago
Knight Therapeutics sees FY25 revenue C$410M-C$420M
PremiumThe Fly
Knight Therapeutics sees FY25 revenue C$410M-C$420M
2M ago
Knight Therapeutics announces CREXONT regulatory submission in Mexico
PremiumThe Fly
Knight Therapeutics announces CREXONT regulatory submission in Mexico
3M ago
AMRX
Knight Therapeutics announces CREXONT NDS accepted for Health Canada review
PremiumThe Fly
Knight Therapeutics announces CREXONT NDS accepted for Health Canada review
3M ago
AMRX
Knight Therapeutics closes acquisition of Paladin
PremiumThe Fly
Knight Therapeutics closes acquisition of Paladin
4M ago
Knight Therapeutics Secures US$50 Million Credit Facility to Fuel Growth
PremiumCompany AnnouncementsKnight Therapeutics Secures US$50 Million Credit Facility to Fuel Growth
4M ago
Knight Therapeutics closes $50M revolving credit facility
Premium
The Fly
Knight Therapeutics closes $50M revolving credit facility
4M ago
Knight Therapeutics Secures Strategic Licensing Agreement with Sumitomo Pharma America, Boosting Market Potential and Investment Appeal
Premium
Ratings
Knight Therapeutics Secures Strategic Licensing Agreement with Sumitomo Pharma America, Boosting Market Potential and Investment Appeal
4M ago
Knight Therapeutics’ Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Knight Therapeutics’ Earnings Call: Growth Amid Challenges
5M ago
Knight Therapeutics: Strong Buy Rating Amid Promising Financial Outlook and Strategic Resilience
PremiumRatings
Knight Therapeutics: Strong Buy Rating Amid Promising Financial Outlook and Strategic Resilience
5M ago
Knight Therapeutics Sees Revenue Growth Amid Strategic Moves
PremiumCompany Announcements
Knight Therapeutics Sees Revenue Growth Amid Strategic Moves
5M ago
Knight Therapeutics sees FY25 revenue C$390M-C$405M
PremiumThe Fly
Knight Therapeutics sees FY25 revenue C$390M-C$405M
5M ago
Knight Therapeutics Reports Q1 2025 Financial Results and Strategic Developments
PremiumCompany AnnouncementsKnight Therapeutics Reports Q1 2025 Financial Results and Strategic Developments
5M ago
Knight Therapeutics reports Q1 EPS C$0.02 vs. (C$0.04) last year
Premium
The Fly
Knight Therapeutics reports Q1 EPS C$0.02 vs. (C$0.04) last year
5M ago
Knight Therapeutics Announces AGM Results and Strategic Approvals
Premium
Company Announcements
Knight Therapeutics Announces AGM Results and Strategic Approvals
5M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >